Board summary
Key figures
18,362
Registered population
50.7% aged 18–64
31.8%
Aged 65+
ICB 20.0% · England 17.9%
1.7%
Ethnic minority (non-White)
0.5% Asian
0.0%
In IMD quintile 1
ICB 30.6% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
3,361
Hypertension register
+4.73% in 3 yrs · England +5.60%
138
SMI register
6.3% of Westmorland and Furness (LAD)'s
317
COPD register
Reviews +1.60% in 3 yrs
Forecast to 2030
3,782
Hypertension patients, 2030
+421 on today
51.5%
QRISK ≥20% on statins, 2030
+0.81pp over 3 yrs
7.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Cardiovascular treatment lags behind strong BP monitoring.
Lipid therapy for QRISK ≥ 20% is 49.8% (England 63.6%), and hypertension control is 67.2% (England 70.3%) despite 91.2% having recent BP readings.
Heart failure reviews and learning disability register fell.
Over 2023 to 2025, heart failure reviews fell 13.9% to 68.2% (England +8.7%), and learning disability prevalence fell 9.1% to 0.4% (78 patients).
Asthma reviews and cervical screening exceed England.
Asthma annual reviews reach 76.6% (England 65.7%) after rising +11.2% over 2023 to 2025, while cervical screening (25-49 yrs) reaches 77.0% (England 66.8%).
Population, age and ethnicity
Patients aged 65+ comprise 31.8% of the list, well above England's 17.9%
Western Dales PCN serves 18,362 registered patients across three practices ranging from 4,560 to 7,392 patients. Patients aged 65+ account for 31.8% (5,830), substantially higher than Westmorland and Furness (25.9%), NHS Lancashire and South Cumbria ICB (20.0%) and England (17.9%). Working-age adults (18–64) comprise 50.7% and children (0–17) 17.6%. Ethnic minority usual residents represent 1.7% (Asian 0.5%, Black 0.2%, Mixed 0.8%, Other 0.2%), while White residents represent 98.3%. Ethnicity figures reflect Census usual residents rather than GP registrations. Forecast population growth to 2030 is 2.0% (LAD 1.7%, ICB 1.7%, England 2.3%), though projection methods remain unverified.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Westmorland and Furness (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Westmorland and Furness LA) | 1,591 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Westmorland and Furness LA) | 736 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Westmorland and Furness LA) | 10.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 7.1 with 0.0% of registered patients in Core20 areas
Average IMD decile across Western Dales PCN is 7.1, compared with 6.0 in Westmorland and Furness (LAD), 5.0 in NHS Lancashire and South Cumbria Integrated Care Board and 5.5 in England. Across all three practices (Bentham Medical Practice, Lunesdale Surgery and Sedbergh Medical Practice), 0.0% of registered patients live in Core20 areas, against 9.2% in Westmorland and Furness (LAD), 30.6% in the ICB and 21.0% in England, with an estimated Core20 count of 0. This distribution does not exclude dispersed rural hardship, which may reflect household-level vulnerability rather than area.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
138
SMI register
0.74% recorded prevalence
78
Learning disability register
0.42% recorded prevalence
7
Care homes, 160 beds
In the PCN catchment
Recorded learning disability prevalence is 0.4% (78 patients), below Westmorland and Furness (0.6%), the ICB (0.6%) and England (0.6%). Severe mental illness is 0.7% (138 patients; England 1.0%). Catchment capacity includes 7 care homes with 160 beds, while the borough recorded 14 people sleeping rough in 2025. Lower recorded prevalence than comparators could reflect demography or register practices, which clinical audit would test.
Severe mental illness: physical health checks
On the severe mental illness register (0.7%), blood pressure checks reached 85.8% (England 83.4%), but BMI recording was 76.1% (England 82.1%), dropping to 66.7% at Bentham Medical Practice. Metabolic monitoring shows practice-level variation.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
3,361
Hypertension register
+4.73%
Register growth, 3 yrs
Westmorland and Furness (LAD) +6.93% · England +5.60%
+3.02pp
BP control, under 80
≤140/90 · +0.24pp aged 80+
+421
More patients by 2030
Forecast 3,782 (19.72%)
Hypertension case-finding and control
Hypertension recorded prevalence is 18.0% (3,361 patients), above England (15.2%) and close to Westmorland and Furness (LAD) (18.2%). While 91.2% of hypertension patients have a recent blood pressure reading (England 90.0%), blood pressure treated to target is 67.2% (England 70.3%, Westmorland and Furness (LAD) 71.7%). In patients aged under 80, control is 61.9% (England 67.8%), with Sedbergh Medical Practice at 52.1%, Bentham Medical Practice at 63.5%, and Lunesdale Surgery at 65.4%. Lower control despite high monitoring suggests treatment escalation protocols could be systematically prioritised.
Lipids and statins
Statin therapy for patients with QRISK ≥ 20% is 49.8%, below England (63.6%) and Westmorland and Furness (LAD) (59.6%). Primary prevention in diabetes reaches 61.0% (England 73.2%). Lower uptake than comparators supports systematic review of high-risk cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 46,602 | £1.20 | £1.64 | £1.86 | £55,922 |
| Cardiovascular (all), 2025 | 66,301 | £3.79 | £3.38 | £3.33 | £251,281 |
The PCN prescribed 46,602 items of lipid-regulating drugs at £1.20 per item, below England (£1.86), Westmorland and Furness (LAD) (£1.68), and the ICB (£1.64), spending £30,757 less than at England's unit cost. Lower unit cost than comparators reflects formulary choices but does not measure prescribing efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+11.22%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.06%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.4% (1,513 patients; England 6.6%, Westmorland and Furness (LAD) 7.9%). Asthma annual reviews reached 76.6% (England 65.7%), leaving 354 patients unreviewed. Second-hand smoke status recording for ages 6–19 was 82.3% (England 78.8%). COPD prevalence is 1.7% (317 patients; England 1.9%), where reviews reached 78.2% (England 76.4%). Prescribing of asthma management items for ages 5–19 was 1,348 rate per 1,000 (England 1,488 rate). Review delivery is strong, but proactive recall can address remaining unreviewed patients.
Cancer register and children's immunisation
Cancer recorded prevalence is 5.7% (1,061 patients; England 3.8%). In Q1 2025/26 childhood immunisations at age 5, MMR dose 1 reached 100.0% and dose 2 reached 90.9%. The 4-in-1 pre-school booster reached 84.8%, below the 95.0% target by 10.2 pp and below the ICB (85.2%). Bentham Medical Practice shows a 27.3 pp MMR dose difference. Immunisation drop-off between doses suggests targeted recall before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
Across NHS Lancashire and South Cumbria ICB in 2022, 52.4% of cancers with a known stage (4,642 of 8,863) were diagnosed at stage 1 or 2 (England 55.3%), sitting 22.6 pp below the 75.0% national ambition by 2028, after falling 1.2 pp since 2013 (53.6%). Known-stage coverage was 74.6% (8,863 of 11,883). These system figures describe ICB pathways, not PCN performance. In Western Dales PCN, cancer prevalence is 5.7% (1,061 patients), rising +11.3% over 2023 to 2025 (England +9.0%). Breast screening coverage is 74.1% (England 69.9%; Westmorland and Furness LAD 76.3%), with Bentham Medical Practice at 68.3%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), University Hospitals of Morecambe Bay NHS Foundation Trust achieved 72.4% on the 62-day cancer standard (12.6 pp below the 85.0% standard), compared with 73.2% at East Lancashire Hospitals NHS Trust, 75.0% at Lancashire Teaching Hospitals NHS Foundation Trust, 73.6% across NHS Lancashire and South Cumbria ICB, and 71.2% nationally. The trust met the 28-day faster diagnosis standard at 78.4% (standard 75.0%; England 79.3%). Diagnostic 6+ week waits were 10.4% overall (England 23.1%), but reached 13.8% for CT (England 9.9%). These figures reflect trust performance rather than PCN delivery.
| Pathways within standard (%) | of Morecambe Bay | Lancashire | East Lancashire | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.39 | 82.90 | 81.50 | 78.39 | 79.32 |
| 31-day treatment (96%) | 95.22 | 89.43 | 98.11 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 72.35 | 75.04 | 73.16 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | of Morecambe Bay | Lancashire | East Lancashire | England |
|---|---|---|---|---|
| MRI | 4.04 | 2.41 | 0.43 | 21.40 |
| CT | 13.76 | 14.97 | 0.15 | 9.92 |
| Echocardiography | 10.55 | 13.85 | 0.00 | 28.48 |
| Colonoscopy | 0.60 | 0.00 | 0.95 | 30.83 |
| Gastroscopy | 1.45 | 0.00 | 1.16 | 29.02 |
| All 15 DM01 tests | 10.44 | 26.65 | 3.25 | 23.14 |
| Community services activity | Westmorland and Furness residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 53,485 | 193,720 |
| Referrals | 6,470 | 29,855 |
| Patients with a contact | 13,445 | 65,335 |
Community services (residents of Westmorland and Furness), Jun 2026 (provisional). In June 2026 (provisional), 249,980 community care activities were recorded for residents of Westmorland and Furness, contributing to 533,345 activities across NHS Lancashire and South Cumbria Integrated Care Board. Adults aged 65+ accounted for 67.9% of borough residents' contacts (36,330 of 53,485). These experimental activity figures reflect submitting providers across the local authority rather than individual PCN registered patients.
Practice variation and patient experience
Overall QOF achievement exceeds national levels, but vaccination achievement varies by 44.0 pp across
In 2025/26, overall QOF achievement across all three practices exceeded England (92.5%), reaching 93.7% at Bentham Medical Practice, 94.4% at Sedbergh Medical Practice, and 95.3% at Lunesdale Surgery. However, vaccination and immunisation domain achievement spanned a 44.0 pp range, from 45.2% at Bentham Medical Practice (below England's 55.2% by 10.0 pp) to 89.1% at Lunesdale Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Lunesdale Surgery | 117 | 0.0 | 93.3% | 80.6% | 94.5% |
| Sedbergh Medical | 110 | 0.0 | 96.9% | 66.5% | 93.3% |
| Bentham Medical | 108 | 0.0 | 83.3% | 67.4% | 92.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven tracked measures trail England over three years, led by heart failure reviews
Across 25 tracked measures, 11 trail England's three-year change. The widest lag is heart failure reviews, with a three-year change of -13.9% over 2023 to 2025 (England +8.7%, Westmorland and Furness (LAD) +1.7%, NHS Lancashire and South Cumbria Integrated Care Board +1.3%), leaving coverage at 68.2% (England 78.5%). Learning disability QOF prevalence fell 9.1% over 2023 to 2025 (England +5.4%). Conversely, strengths include asthma reviews (+11.2%; England +4.4%) and non-frail diabetes HbA1c control (+9.0%; England +4.4%), reaching 58.1% (England 57.4%). These divergent trends suggest review capacity may be concentrated unevenly across long-term condition pathways.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Learning disability register
Diabetes statin (CVD)
QRISK statin treatment
Breast screening (53-70)
Asthma reviews
Diabetes statin (no CVD)
Diabetes HbA1c control
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Westmorland and Furness (LAD) | Asset | PCN | Westmorland and Furness (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 7 (160 beds) | n/a | Schools (catchment) | 39 | n/a |
| Children's centres | no data | 12 | Places of worship | 79 | 316 |
| Libraries | 3 | 14 | Food banks (VCS) | 1 | 2 |
| Day centres (VCS) | 1 | 2 | Children and young people (VCS) | n/a | 3 |
| Carers support groups (VCS) | n/a | 2 | Primary schools (LA maintained) | 17 | 82 |
| Primary academies | n/a | 27 | Special schools | 1 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Cardiovascular treatment and lipid escalation
Among 3,361 hypertension patients (18.0%), 91.2% have a recent reading, but control is 67.2% (England 70.3%) and under-80 control is 61.9% (England 67.8%). QRISK ≥ 20% lipid therapy is 49.8% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Asthma annual review recall
On the asthma register of 1,513 patients (8.4% prevalence; England 6.6%), annual review coverage is 76.6% (above England's 65.7%), leaving a modelled gap of 354 patients unreviewed. For discussion, the PCN could sustain standardised review templates and offer flexible or remote review slots to reach the remaining unreviewed patients. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Learning disability register validation
Learning disability prevalence is 0.4% (78 of 18,362 patients) after falling 9.1% over 2023 to 2025, below the LAD and England (both 0.6%), giving a modelled gap of +23 to +30 patients. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register audit (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| SMI physical health check completion (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension medication titration review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted breast screening recall outreach (p7) | Breast screening coverage: aged 53 to 70 years old | — | Practice |
| Option 1 · Cardiovascular treatment and lipid escalation (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
